Janux Therapeutics, Inc. (JANX)

42,00 -0,37 (-0,87%) Börsenschluss: 04:00PM EDT

Janux Therapeutics, Inc.

10955 Vista Sorrento Parkway
Suite 200
San Diego, CA 92130
United States
858-751-4493
https://www.januxrx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 68

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. David Alan Campbell Ph.D.	President, CEO & Director	1,04M	N/A	1960
Mr. Charles M. Winter	Chief Technical Officer	590,4k	N/A	1969
Mr. Byron Robinson J.D., Ph.D.	Chief Strategy Officer	723k	N/A	1965
Mr. Tighe M. Reardon C.F.A., CPA	Acting Chief Financial Officer	N/A	N/A	1976
Dr. Tommy Diraimondo Ph.D.	Chief Scientific Officer	N/A	N/A	1986
Mr. James Pennington	General Counsel	N/A	N/A	N/A
Ms. Brenda Van Vreeswyk	Head of Human Resources	N/A	N/A	N/A
Mr. Andy Hollman Meyer	Chief Business Officer	N/A	N/A	1984

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Corporate Governance

Janux Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 9. Die grundlegenden Scores sind Audit: 6, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.